Exploring potential use of pharmacogenomic testing in primary care
Research type
Research Study
Full title
A mixed-methods study exploring patient-professional perspectives for the implementation of pharmacogenomic testing in the UK Primary Care setting: developing clinical pathways and assessing the cost effectiveness.
IRAS ID
336604
Contact name
Sadaf Qureshi
Contact email
Sponsor organisation
University of Nottingham
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
2 years, 0 months, 30 days
Research summary
The effects of a medicine can vary greatly between individuals. Although medicines work well for most people, differences in people’s genetic makeup can mean that they work less for some and show side effects in others. Pharmacogenomics is the study of how genes affect a person’s response to medicines. By using pharmacogenomic testing, there is a potential to improve patient care through decreasing side effects of medicines, including serious side effects. However, there is limited use of pharmacogenomic testing in the UK primary care. This is partly related to limited understanding on how pharmacogenomic testing could work and how this may impact on patients and clinicians use in primary care.
The aim of this study is to understand how to increase the use of pharmacogenomic testing in routine clinical practice in UK primary care setting. This research will involve three workstreams:-
• Workstream 1: this involves interviewing GPs, pharmacists, nurses, and patients to understand their views on the potential use of pharmacogenomic testing.
• Workstream 2: this workstream building on the findings form workstream 1 will involve presenting the findings from the first set of interviews to a group of experts, to produce pharmacogenomic-guided clinical pathways for use in practices by GPs, pharmacists, or nurses. This will include looking at the roles and responsibilities of GPs, pharmacists, and nurses to see who the best-placed healthcare professional would be to take on the use of pharmacogenomic testing to aid prescribing in primary care.
• Workstream 3: The final workstream of this research is to examine if these pathways are a good use of healthcare resources. The findings from these studies will be brought together to advise how primary care can use pharmacogenomic tests in the future.
The study duration will be between 1-2 years.
REC name
London - Queen Square Research Ethics Committee
REC reference
24/PR/1088
Date of REC Opinion
18 Oct 2024
REC opinion
Further Information Favourable Opinion